Brief: Rani Therapeutics Receives Feedback From Pre-Ind Meeting With FDA Provides Pipeline Update

Rani Therapeutics Holdings

05/01/2023 21:56

Jan 5 (Reuters) - Rani Therapeutics Holdings Inc
 RANI.O :
    * RANI THERAPEUTICS RECEIVES FEEDBACK FROM PRE-IND MEETING
WITH
FDA; PROVIDES PIPELINE UPDATE
    * RANI THERAPEUTICS HOLDINGS INC - PRELIMINARY FEEDBACK FROM
FDA
ON RT-102 DEVELOPMENT PLANS; 505(B)(2) PATHWAY FOR RT-102 COULD
BE SUITABLE
    * RANI THERAPEUTICS HOLDINGS-MULTIPLE ANTICIPATED CLINICAL
MILESTONES EXPECTED IN 2023, INCLUDING INITIATION OF PHASE 2
STUDY OF RT-102 IN OSTEOPOROSIS
    * RANI THERAPEUTICS HOLDINGS INC - EXPECTS RT-102 PHASE 2
INITIATION IN SECOND HALF OF 2023
    * RANI THERAPEUTICS HOLDINGS - HAS ABOUT $99 MILLION IN
CASH, CASH
EQUIVALENTS, RESTRICTED CASH EQUIVALENTS AND MARKETABLE
SECURITIES AS OF DEC 31, 2022

Source text for Eikon:  ID:nGNX9353qy 
Further company coverage:  RANI.O 
 ((Reuters.Briefs@thomsonreuters.com;;))